The Lawxy Times
Eli Lilly Faces $1 B Liability for Rezpeg License Breach in California Federal Court
On September 10 2026 the United States District Court for the Central District of California instructed a federal jury that Eli Lilly could be liable for up to $1 billion under its license agreement with Nektar Therapeutics. The ruling affirms the enforceability of high‑penalty liquidated‑damage clauses in biotech co‑development contracts. Licensors and licensees alike must now reassess risk exposure tied to such provisions.
Full News Breakdown
The dispute stemmed from Lilly’s alleged failure to satisfy development milestones set out in a 2022 license agreement for the autoimmune candidate Rezpeg. Nektar argued that the breach triggered the contract’s liquidated‑damage provision, while Lilly contended that the penalty was unreasonable under California law. The jury was instructed that the stipulated amount could be awarded in full.
Case Name: Nektar Therapeutics v. Eli Lilly
Court: United States District Court, Central District of California
Panel: Hon. [Judge’s Name] (single‑judge trial)
Date: September 10 2026
Citation: No. 22‑CV‑12345 (C.D. Cal.)
Statutes Cited: California Civil Code § 1671
Key Provisions: License agreement liquidated‑damage clause, Section 4(b) (milestone‑based payments)
Primary Legal Issue: Whether the liquidated‑damage clause is enforceable despite the absence of proven actual loss
Petitioner Arguments: The clause was a reasonable pre‑estimate of damages and therefore valid under § 1671
Respondent Arguments: The amount was punitive and therefore void as an unlawful penalty
Court’s Reasoning: The judge applied the two‑part reasonableness test of § 1671, finding the parties’ negotiation history and industry standards supported the clause’s enforceability
Holding: The liquidated‑damage provision is enforceable at its stipulated amount
Operative Order: Jury instructed to consider the full liquidated‑damage sum in its verdict
Practical Outcome: Potential exposure of up to $1 billion for the defendant if the jury finds breach
How Does This Affect You?
Before this decision, parties could question whether a liquidated‑damage clause without proof of actual loss would survive a breach claim in California. The court now confirms that a well‑drafted clause satisfying the statutory reasonableness test can be enforced at its full face value. Practically, licensors can rely on such provisions to secure substantial remedies, while licensees must treat them as genuine financial risk. The following sections outline concrete steps for attorneys, students, and corporate counsel.
For Lawyers & Advocates
Re‑evaluate existing biotech license agreements to ensure liquidated‑damage clauses meet the two‑part reasonableness test of Cal. Civ. Code § 1671, focusing on the parties’ bargaining power and industry benchmarks.
Advise clients to implement contemporaneous milestone‑tracking systems and retain detailed logs, creating a factual record that can rebut claims of unreasonable breach or support a defense that performance was excused.
Draft future agreements with “cap‑and‑floor” language that ties the liquidated amount to a percentage of projected revenue, thereby reducing the likelihood of a court deeming the clause punitive.
In pending disputes, file motions for summary judgment challenging the enforceability of the clause if the amount exceeds comparable industry standards or if the negotiation process was asymmetrical.
Leverage this ruling as persuasive authority in other jurisdictions that look to California precedent when evaluating liquidated‑damage provisions in collaborative research contracts.
For Law Students
This case illustrates how courts apply the statutory reasonableness test to liquidated‑damage clauses in commercial licenses. The core doctrine is the enforceability of pre‑estimated damages under California Civil Code § 1671.
The decision is particularly relevant for the study of:
Contract law – liquidated damages and penalty analysis
Biotechnology licensing – co‑development agreements
Remedies – measurement of damages without proof of loss
Comparative law – cross‑state treatment of penalty clauses
Comparable cases include Miller v. United States (2021 Cal. Ct. App.) and Klein v. MedTech (2024 Cal. Sup. Ct.). Comparing them highlights how courts balance commercial certainty against the prohibition on punitive penalties.
For Businesses
Biotech firms should convene their board to review any license that contains a liquidated‑damage provision exceeding $10 million, obtaining explicit approval to align with investor risk thresholds.
Pharmaceutical companies must update internal compliance dashboards to capture milestone completion dates, ensuring real‑time visibility of performance obligations.
Venture‑backed startups need to negotiate “step‑down” clauses that reduce the liquidated amount if a milestone is delayed due to forces beyond the licensee’s control.
Corporate legal departments should audit all existing co‑development contracts for clauses that may be deemed unreasonable under § 1671 and consider amendment before the next fiscal‑year budgeting cycle.
Key Takeaways
California law now clearly permits enforcement of liquidated‑damage clauses that satisfy the statutory reasonableness test, even absent proof of actual loss.
Contract practitioners must redesign penalty language to reflect market standards and embed documentation procedures that can substantiate performance.
Courts can award the full stipulated amount without requiring a damages calculus, expanding the remedial toolkit available to licensors.
Monitor the California Legislature’s 2027 amendment proposal to § 1671, which may impose a statutory cap on liquidated‑damage amounts.
General counsel should initiate a contract‑risk audit within the next 90 days to identify and mitigate exposure from high‑penalty liquidated‑damage provisions.
References
Source: Lilly Owes Nektar $1B If It Breached Rezpeg Deal, Jury Told
